An explanation for the different inhibitory characteristics of human serum butyrylcholinesterase phenotypes deriving from inhibition of atypical heterozygotes

Chem Biol Interact. 1999 May 14:119-120:159-64. doi: 10.1016/s0009-2797(99)00024-1.

Abstract

The time course of inhibition of butyrylcholinesterase (EC 3.1.1.8) by the dimethylcarbamate Ro 02-0683 in sera taken from patients heterozygous for the usual (U), atypical (A), K or J variants was followed using propionylthiocholine as substrate. Data obtained were used to determine rate constants of inhibition together with the contribution made by each variant to total enzyme activity. The findings substantiate earlier reports that J and K mutations lead to quantitative changes in the concentration of usual enzyme in contrast to the qualitative changes of the atypical variant. The contribution of the atypical enzyme to the total activity in serum from UA, AK and AJ heterozygotes was respectively 17-20, 24-31 and 34-53%. The altered ratios of atypical to usual, K or J enzyme in UA, AK and AJ together with the constants on the usual enzyme alone, explain the differences in observed inhibitor numbers which enable these heterozygotes to be identified.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apnea / chemically induced
  • Apnea / enzymology
  • Butyrylcholinesterase / blood*
  • Butyrylcholinesterase / genetics*
  • Carbamates / pharmacokinetics
  • Carbamates / pharmacology
  • Cholinesterase Inhibitors / pharmacokinetics*
  • Cholinesterase Inhibitors / pharmacology
  • Dibucaine / pharmacokinetics
  • Dibucaine / pharmacology
  • Genetic Carrier Screening / methods*
  • Humans
  • Kinetics
  • Neuromuscular Depolarizing Agents / adverse effects
  • Neuromuscular Depolarizing Agents / therapeutic use
  • Phenotype
  • Quaternary Ammonium Compounds / pharmacokinetics
  • Quaternary Ammonium Compounds / pharmacology
  • Sodium Fluoride / pharmacokinetics
  • Sodium Fluoride / pharmacology
  • Succinylcholine / adverse effects
  • Succinylcholine / therapeutic use
  • Thiocholine / analogs & derivatives
  • Thiocholine / metabolism

Substances

  • Carbamates
  • Cholinesterase Inhibitors
  • Neuromuscular Depolarizing Agents
  • Quaternary Ammonium Compounds
  • Ro 20683
  • propionylthiocholine
  • Thiocholine
  • Sodium Fluoride
  • Butyrylcholinesterase
  • Succinylcholine
  • Dibucaine